Qualitative and Quantitative Analysis of the Major Constituents in Shexiang Tongxin Dropping Pill by HPLC-Q-TOF-MS/MS and UPLC-QqQ-MS/MS.

Qualitative and Quantitative Analysis of the Major Constituents in Shexiang Tongxin Dropping Pill by HPLC-Q-TOF-MS/MS and UPLC-QqQ-MS/MS.
复制标题

DOI:
10.3390/molecules201018597
复制
发表时间:
2015-10-14
期刊:
Molecules (Basel, Switzerland)
影响因子:
--
通讯作者:
Peng J
Peng J
中科院分区:
其他
文献类型:
--
作者:
Chen D;Lin S;Xu W;Huang M;Chu J;Xiao F;Lin J;Peng J

文献摘要

参考文献

被引文献

相似文献

麝香通心滴丸是由人参总皂苷、人工牛黄、熊胆、蟾酥、丹参等组成的中药制剂。STP已在中国和东南亚广泛用于心血管疾病的治疗。在这项研究中,使用高效液相色谱-四极杆飞行时间串联质谱定性分析方法,用于鉴定STP中的主要成分。根据保留时间和质谱,通过与对照品和文献数据的比较,鉴定了41个组分。此外,使用超高效液相色谱-三重四极杆串联质谱在多反应监测模式下,我们定量了13个已鉴定的成分(CNORg 1,CNORk 3,华蟾酥毒基,arenobufagin,蟾蜍灵,脂蟾毒配基,丹参酮IIA,牛磺酸,牛磺熊去氧胆酸,牛磺胆酸,胆酸,脱氧胆酸,和鹅去氧胆酸)。结果表明,该方法适用于STP产品的常规分析和质量控制,并为进一步的体内药代动力学研究提供了基础数据。
Shexiang Tongxin dropping pill (STP) is a traditional Chinese medicine formula that consists of total saponins of ginseng, synthetic Calculus bovis, bear gall, Venenum bufonis, borneol and Salvia miltiorrhiza. STP has been widely used in China and Southeast Asia for the treatment of cardiovascular diseases. In this study, a qualitative analytical method using high performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry was developed for identification of the major constituents in STP. Based on the retention time and MS spectra, 41 components were identified by comparison with reference compounds and literature data. Moreover, using ultra-performance liquid chromatography coupled with triple-quadrupole tandem mass spectrometry in multiple-reaction monitoring mode, we quantified 13 of the identified constituents (ginsenoside Rg1, ginsenoside Rk3, cinobufagin, arenobufagin, bufalin, resibufogenin, tanshinone IIA, taurine, tauroursodeoxycholic acid, taurocholic acid, cholic acid, deoxycholic acid, and chenodeoxycholic acid). These results suggest that this new approach is applicable for the routine analysis and quality control of STP products and provides fundamental data for further in vivo pharmacokinetical studies.
DOI: 10.1021/jf950713e
发表时间: 1996-09-01
影响因子: 6.1
作者:
Pfister, S;Meyer, P;Pfander, H
通讯作者: Pfander, H
DOI: 10.1016/j.jpba.2013.02.021
发表时间: 2013-06-01
影响因子: 3.4
作者:
Wang, Yanyan;He, Shan;Zhang, Qinglin
通讯作者: Zhang, Qinglin
DOI: 10.1016/j.jpba.2013.10.042
发表时间: 2014-02-15
影响因子: 3.4
作者:
Wang, Dan-dan;Liang, Jian;Guo, De-An
通讯作者: Guo, De-An
DOI: 10.1142/s0192415x11009470
发表时间: 2011
期刊: The American journal of Chinese medicine
影响因子: --
作者:
Wang CZ;Kim KE;Du GJ;Qi LW;Wen XD;Li P;Bauer BA;Bissonnette MB;Musch MW;Chang EB;Yuan CS
通讯作者: Yuan CS
DOI: 10.1002/rcm.6226
发表时间: 2012-06-15
影响因子: 2
作者:
Chernetsova, Elena S.;Crawford, Elizabeth A.;Morlock, Gertrud E.
通讯作者: Morlock, Gertrud E.